However, as PD-1 has recently been demonstrated to act as a tumor suppressor in T-cell malignancies [185], it has been discussed that targeting PD-1 ligands may potentially offer a safer option in CTCL. This evidence concerns the gene PDCD1 and primary cutaneous T-cell non-Hodgkin lymphoma.